Daniel Miller, MD
Urology · Portland, ORNPI 1508032525
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,263 of the $4,222 with a category attached, or 77.3%. 38 manufacturers reported payments, led by Neotract Inc. at 33.1% of the total. Reporting peaked in 2019 at $2,139 and has fallen 63.8% since, to $775 in 2025.
Across 133 payments — averaging $31.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$1K
- Astellas Pharma US Inc$548
- Bayer$193
- AbbVie$171
- Pfizer$147
- Ambu Inc.$144
- plus $2K from 32 others
What the payments were for
- Travel & lodging$81619%
- Food & beverage$3,26377%
- Education$1273%
- Gifts$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 12 | $1,396 |
| Astellas Pharma US Inc | 24 | $548 |
| Bayer | 8 | $193 |
| AbbVie(2 entities) | 9 | $171 |
| Pfizer | 8 | $147 |
| Ambu Inc. | 1 | $144 |
| Procept Biorobotics Corporation | 1 | $140 |
| Ferring Pharmaceuticals Inc. | 7 | $119 |
| Rochester Medical Corporation | 4 | $110 |
| Myriad Genetic Laboratories, Inc. | 6 | $109 |
| Angiodynamics, Inc. | 1 | $85 |
| Progenics Pharmaceuticals, Inc. | 3 | $83 |
| Accord Healthcare, Inc. | 4 | $80 |
| Endo Pharmaceuticals Inc. | 5 | $79 |
| Sumitomo Pharma America, Inc. | 3 | $75 |
| Tolmar, Inc. | 3 | $67 |
| Urogen Pharma, Inc. | 2 | $67 |
| Johnson & Johnson(2 entities) | 3 | $60 |
| Boston Scientific | 2 | $51 |
| Alnylam Pharmaceuticals Inc. | 2 | $48 |
| Coloplast | 3 | $47 |
| Olympus America Inc. | 2 | $43 |
| Travere Therapeutics, Inc. | 5 | $36 |
| 180 Medical, Inc. | 1 | $29 |
| Dendreon Pharmaceuticals LLC | 1 | $28 |
| Axonics, Inc. | 1 | $25 |
| Amgen | 1 | $25 |
| Teleflex LLC | 1 | $24 |
| Myovant Sciences Inc. | 1 | $24 |
| Agiliti Surgical, Inc. | 1 | $24 |
| Valencia Technologies Corporation | 1 | $22 |
| Convatec Inc. | 1 | $20 |
| Endo USA, Inc. | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $17 |
| Merck | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $15 |
| BD | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$1,087
- AquaBeam Robotic System$140
How this compares
$4,222 in reported general payments places this provider in the 75th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 66 | $50,923 |
| GemtesaVibegron | 31 | $33,251 |
| Tamsulosin Hcl | 517 | $7,017 |
| Finasteride | 525 | $6,391 |
| Solifenacin Succinate | 100 | $2,759 |
| Trospium Chloride | 31 | $2,678 |
| Oxybutynin Chloride ErOxybutynin Chloride | 87 | $2,353 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 79 | $1,979 |
| Methenamine Hippurate | 14 | $1,638 |
| Estradiol | 22 | $1,387 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $979 |
| Dutasteride | 25 | $838 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 28 | $439 |
| Oxybutynin Chloride | 43 | $293 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 39 | $173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $548 | $50,92366 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $75 | $33,25131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 153 urology providers in Oregon.
Other urology in Portland
- Lance MarrPortland$323K
- da David JiangPortland$65K
- Amir PatelPortland$36K
- James TycastPortland$35K
- Sudhir IsharwalPortland$30K
- Ian MetzlerPortland$23K
- Sara Spettel AliyarPortland$21K
- Daniel JanoffPortland$15K
- James BreseePortland$14K
- Stanley MyersPortland$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.